Related Experiment Video
Updated: Jan 5, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Olivia G Taylor1,2, Joshua S Brzozowski1,2, Kathryn A Skelding1,2
1Faculty of Health and Medicine, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Abstract:
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis. The existing treatments have had limited success in increasing overall survival. Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets. The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour. Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results. This review will outline the status of several of these promising targeted therapies.
Insights
Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis. This review explores promising targeted therapies that may overcome the blood-brain barrier to improve treatment outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary brain tumor, characterized by a dismal prognosis.
- Current therapeutic strategies for GBM have shown limited efficacy in improving patient survival rates.
- The blood-brain barrier (BBB) presents a significant obstacle in delivering effective treatments to brain tumors.
Purpose of the Study:
- To review the current status of promising targeted therapies for glioblastoma multiforme.
- To identify key molecules driving the malignant phenotype of GBM for potential therapeutic targeting.
- To discuss targeted therapies that demonstrate the ability to penetrate the blood-brain barrier.
Main Methods:
- Literature review of preclinical and clinical studies on targeted therapies for GBM.
- Analysis of molecular mechanisms underlying GBM development and progression.
- Evaluation of drug delivery strategies across the blood-brain barrier.
Main Results:
- Several targeted therapies show promise in preclinical models of GBM.
- Certain agents have demonstrated the capacity to cross the blood-brain barrier.
- Understanding GBM's molecular drivers is crucial for developing effective treatments.
Conclusions:
- Targeted therapies offer a promising avenue for improving GBM treatment outcomes.
- Overcoming the BBB is a critical challenge that is being addressed by novel drug delivery systems.
- Further research into GBM-specific molecular targets and BBB-penetrant therapies is warranted.
